TriSalus Life Sciences, Inc. Investigation

Company: TriSalus Life Sciences, Inc.

Ticker: (NASDAQ) TLSI

See If You Qualify For Monetary Reward

Join the TriSalus Life Sciences, Inc. Class Action Lawsuit

Investigation Details

TLSI reported Q1 2026 revenue of $8.9 million. Wall Street consensus had projected $9.4 million -- a shortfall of approximately $500,000, or more than 5%. The miss arrived approximately two months after CEO Mary Szela reaffirmed full-year 2026 revenue guidance of $60 million to $62 million on the Q4 2025 earnings call on March 5, 2026. Alongside the Q1 miss, the company cut its full-year 2026 revenue outlook to $54 million to $57 million -- a reduction of up to $8 million from the range reaffirmed in March 2026. The revised midpoint of $55.5 million represented a roughly 9% reduction from the prior midpoint of $61 million.

Frequently Asked Questions

How do I join the lawsuit against TriSalus Life Sciences, Inc. (NASDAQ: TLSI)?

Investors who purchased shares of TriSalus Life Sciences, Inc. (NASDAQ: TLSI) during the class period (May 14, 2021 - May 14, 2026) can join by submitting their transaction details through this case page.

Ensure your purchase falls within the class period
Provide basic transaction and loss details
Submit your information before the deadline

The lead plaintiff deadline for this case is To be determined, so investors should act quickly to protect their rights.

Who is eligible for the TriSalus Life Sciences, Inc. lawsuit?

Anyone who bought shares of TriSalus Life Sciences, Inc. (NASDAQ: TLSI) during May 14, 2021 - May 14, 2026 and suffered financial losses may qualify.

What is the lead plaintiff deadline to join the TriSalus Life Sciences, Inc. case?

The lead plaintiff deadline for the TriSalus Life Sciences, Inc. lawsuit is To be determined. Investors should act quickly to avoid missing this deadline.

What is the class period for TriSalus Life Sciences, Inc.?

The class period for TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is May 14, 2021 - May 14, 2026, during which investors may have been affected by alleged misconduct.

Can I still join the TriSalus Life Sciences, Inc. lawsuit if I sold my shares?

Yes. Investors who purchased TriSalus Life Sciences, Inc. shares during May 14, 2021 - May 14, 2026 may still qualify, even if they sold their shares later.

How much compensation can I receive from the TriSalus Life Sciences, Inc. lawsuit?

Compensation depends on the total losses and the final settlement. Eligible investors in the TriSalus Life Sciences, Inc. case may receive a portion of the recovery.

Do I need to pay to participate in the TriSalus Life Sciences, Inc. case?

No, most securities fraud cases involving TriSalus Life Sciences, Inc. operate on a contingency basis, meaning there are no upfront costs unless there is a recovery.

Will I need to appear in court for the TriSalus Life Sciences, Inc. lawsuit?

In most cases, investors do not need to appear in court. The legal team manages the TriSalus Life Sciences, Inc. case on behalf of participants.

What documents are required for the TriSalus Life Sciences, Inc. lawsuit?

To participate in the TriSalus Life Sciences, Inc. lawsuit, investors may need to provide transaction records, purchase dates, number of shares, and loss details.

What happens after I submit my trade information for TriSalus Life Sciences, Inc.?

After submission, your details for the TriSalus Life Sciences, Inc. case will be reviewed, and you may be contacted regarding eligibility or next steps.

Is this legal advice for the TriSalus Life Sciences, Inc. lawsuit?

No, this page provides information about the TriSalus Life Sciences, Inc. case and does not constitute legal advice or create an attorney-client relationship.

Why should I act quickly on the TriSalus Life Sciences, Inc. case?

The lead plaintiff deadline for the TriSalus Life Sciences, Inc. lawsuit is To be determined. If you are an investor, you may have the opportunity to seek appointment as lead plaintiff or remain an absent class member.